EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients

被引:231
作者
Bower, M
Newlands, ES
Holden, L
Short, D
Brock, C
Rustin, GJS
Begent, RHJ
Bagshawe, KD
机构
[1] CHARING CROSS HOSP,MED ONCOL UNIT,LONDON,ENGLAND
[2] ROYAL FREE HOSP,DEPT CLIN ONCOL,LONDON NW3 2QG,ENGLAND
[3] MT VERNON HOSP,MT VERNON CTR CANC,NORTHWOOD,MIDDX,ENGLAND
关键词
D O I
10.1200/JCO.1997.15.7.2636
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the results of etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) chemotherapy in women with high-risk gestational trophoblastic tumors (GTT) and to document the middle- and long-term toxicity of the regimen. Patients and Methods: A total of 272 consecutive women with high-risk GTT, including 121 previously treated patients, were treated with weekly EMA/CO, The median follow-up duration is 4.5 years (range, 1 to 16). Results: The cumulative 5-year survival rate is 86.2% (95% confidence interval, 81.9% to 90.5%), No deaths from GTT have occurred later than 2 years after the start of EMA/CO. In a multivariate model, adverse prognostic factors were the presence of liver metastases (P<.0001), interval from antecedent pregnancy (P<.0001), brain metastases (P=.0008), and term delivery of antecedent pregnancy (P=.045), There were 11 (4%) early deaths, while 213 patients (78%) achieved a complete remission. Forty-seven (17%) developed drug resistance to EMA/CO, of whom 33 (70%) were salvaged by further cisplatin-based chemotherapy and surgery, Two women developed acute myeloid leukemia, two cervical malignancy, and one gastric adenocarcinoma after EMA/CO, More than half (56%) of the women who had fertility-conserving surgery and who have been in remission at least 2 years have become pregnant since the completion of EMA/CO, with 112 live births, including three infants with congenital abnormalities, Conclusion: EMA/CO is an effective and well-tolerated regimen for high-risk GTT, More than half of the women will retain their fertility; however, there is a small bur significant risk of second malignancy. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:2636 / 2643
页数:8
相关论文
共 26 条
[1]  
BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO
[2]  
2-E
[3]  
BERKOWITZ RS, 1994, J REPROD MED, V39, P228
[4]  
BOLIS G, 1989, OBSTET GYNAECOL SURV, V44, P394
[5]   GESTATIONAL CHORIOCARCINOMA [J].
BOWER, M ;
BROCK, C ;
FISHER, RA ;
NEWLANDS, ES ;
RUSTIN, GJS .
ANNALS OF ONCOLOGY, 1995, 6 (05) :503-508
[6]  
Bower M, 1996, CLIN CANCER RES, V2, P897
[7]  
BOWER M, 1994, LEUKEMIA, V8, P226
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   Gestational trophoblastic disease with liver metastases: The Charing Cross experience [J].
Crawford, RAF ;
Newlands, E ;
Rustin, GJS ;
Holden, L ;
AHern, R ;
Bagshawe, KD .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (01) :105-109
[10]  
FELDMAN S, 1995, SEMIN ONCOL, V22, P166